Scholar Rock, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.scholarrock.com
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06445075
- Locations
- 🇺🇸
ProSciento CRU, Chula Vista, California, United States
🇺🇸AdventHealth Translational Research Institute, Orlando, Florida, United States
🇺🇸Great Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05626855
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇧🇪CHR Citadelle, Liege, Belgium
🇫🇷Hopital Trousseau - I-Motion, Paris, France
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05156320
- Locations
- 🇺🇸
Oregon Health & Sciences University, Portland, Oregon, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT04291079
- Locations
- 🇺🇸
University of California - San Diego, La Jolla, California, United States
🇺🇸Memorial Cancer Institute - South Broward Hospital District, Hollywood, Florida, United States
🇺🇸BUMC Mary Crowley Cancer Research Centers, Dallas, Texas, United States
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03921528
- Locations
- 🇺🇸
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States